ebv-tcr-t cells
Cell therapyexperimental
Clinical trial activity
6 trials · 6 clinical orgs · 0 marketing orgs
Phase 1
6
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Dec 1, 2019 (NCT04156217)
Timeline
2010s
- Jan 1, 2019
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- epstein-barr virusImmunity, passive
epstein-barr virus immunity, passive
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07162012 | Early Phase 1 (Phase 1) | Sep 30, 2025 | Jiao Tong University |
| NCT06909110 | Phase 1/Phase 2 (Phase 2) | Apr 30, 2025 | Stanford University |
| NCT06119256 | Phase 1 | Aug 1, 2023 | People's Liberation Army of China |
| NCT06135922 | Phase 1 | Aug 1, 2023 | People's Liberation Army of China |
| NCT04364178 | Phase 1/Phase 2 (Phase 2) | Jun 1, 2020 | University of Pittsburgh |
| NCT04156217 | Phase 1 | Dec 1, 2019 | China Immunotech, Ludaopei Hospital |
Showing 6 of 6 trials
Page 1 / 1
Organizations
Research & Development (6)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| People's Liberation Army of China | Government | 2 | 2 | 1 | 2023 |
| China Immunotech | For profit | 1 | 0 | 1 | 2019 |
| Jiao Tong University | Academic/Hospital | 1 | 1 | 1 | 2025 |
| Ludaopei Hospital | Academic/Hospital | 1 | 1 | 1 | 2019 |
| Stanford University | Academic/Hospital | 1 | 1 | 1 | 2025 |
| University of Pittsburgh | Academic/Hospital | 1 | 1 | 1 | 2020 |
6 organizations
Page 1 / 1